The average price of brand-name prescription drugs rose almost 130 times faster than inflation in 2015 — 15.5 percent compared with 0.1 percent. New data points to increasing medication affordability problems for older adults, putting many of them at risk, according to a new report.
Researchers from the AARP Public Policy Institute studied trends in the retail prices of 268 brand name drugs widely used by older Americans between 2006 and 2015. Continue reading
We may need a new hashtag to supplement #surprisemedbills. Perhaps #shockingmedbills would fit because some bills are just that.
Recent coverage about a new mom in Utah who was charged $39.35 just to hold her newborn is a good example. Continue reading
Buying health insurance – or understanding what our plans cover and how much we have to pay – isn’t easy. Moreover, the people we interview about their health plans and ACA shopping experiences can be just as confused as everyone else. Headlines about the health law and affordability and limited choices can confuse people, or make them assume their own costs are going up – which may not be true. Several million people who are eligible for ACA subsidies still aren’t getting them – and many don’t realize they may be eligible for financial assistance. Continue reading
Bad debt? Or charity care? Sean Hamill of the Pittsburgh Post-Gazette recently wrote an interesting story about how hospitals increasingly are re-categorizing the health care bills of low-income patients in a fashion that may be helping the hospital more than the patient.
Some angles in this story are especially timely as the 2017 Affordable Care Act enrollment season is about to begin. Continue reading
Mylan’s price hike for its EpiPen allergy medication is just the latest example of health care costs pressuring consumers, Consumers Union’s Lynn Quincy told AHCJ members in a recent webcast.
Quincy, who leads the consumer-advocacy group’s Healthcare Value Hub and has backed efforts to curb rising drug prices, pointed to other recent price increases such as those by drugmakers Valeant and Turing as symptoms of a massive “market failure.” Continue reading